Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-… Read more
Denali Therapeutics Inc - Asset Resilience Ratio
Denali Therapeutics Inc (DNLI) has an Asset Resilience Ratio of 71.73% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Denali Therapeutics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Denali Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $757.24 Million | 71.73% |
| Total Liquid Assets | $757.24 Million | 71.73% |
Asset Resilience Insights
- Very High Liquidity: Denali Therapeutics Inc maintains exceptional liquid asset reserves at 71.73% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Denali Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Denali Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Denali Therapeutics Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Denali Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 47.84% | $657.37 Million | $1.37 Billion | -30.80pp |
| 2023-12-31 | 78.64% | $907.40 Million | $1.15 Billion | +2.06pp |
| 2022-12-31 | 76.57% | $1.12 Billion | $1.46 Billion | +35.84pp |
| 2021-12-31 | 40.73% | $571.93 Million | $1.40 Billion | -19.27pp |
| 2020-12-31 | 60.00% | $962.55 Million | $1.60 Billion | -0.72pp |
| 2019-12-31 | 60.72% | $335.91 Million | $553.23 Million | +2.23pp |
| 2018-12-31 | 58.49% | $387.17 Million | $661.98 Million | +19.89pp |
| 2017-12-31 | 38.60% | $187.85 Million | $486.72 Million | -12.49pp |
| 2016-12-31 | 51.09% | $138.48 Million | $271.07 Million | -- |